Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Autolus Therapeutics plc
  6. Summary
    AUTL   US05280R1005

AUTOLUS THERAPEUTICS PLC

(AUTL)
  Report
Delayed Nasdaq  -  04:00 2022-06-24 pm EDT
2.570 USD   +2.80%
06/21European ADRs Rise Sharply in Tuesday Trading
MT
06/15European ADRs Move Higher in Wednesday Trading
MT
06/14Truist Securities Adjusts Price Target for Autolus Therapeutics to $11 From $13, Maintains Buy Rating
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/17/2022 06/21/2022 06/22/2022 06/23/2022 06/24/2022 Date
2.22(c) 2.39(c) 2.36(c) 2.5(c) 2.57(c) Last
185 099 109 128 92 087 225 626 123 456 Volume
+7.77% +7.66% -1.26% +5.93% +2.80% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 0,77 M - -
Net income 2022 -157 M - -
Net cash position 2022 278 M - -
P/E ratio 2022 -1,51x
Yield 2022 -
Sales 2023 12,6 M - -
Net income 2023 -170 M - -
Net cash position 2023 279 M - -
P/E ratio 2023 -1,50x
Yield 2023 -
Capitalization 234 M 234 M -
EV / Sales 2022 -57,0x
EV / Sales 2023 -3,62x
Nbr of Employees 326
Free-Float 9,71%
More Financials
Company
Autolus Therapeutics PLC is a biopharmaceutical company. The Company is focused on developing programmed T cell therapies for the treatment of cancer. It has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. Its lead clinical programs include AUTO1 (obecabtagene autoleucel, Obe-Cel), AUTO1/22, AUTO4, AUTO6NG and AUTO8. Obe-cel is a CD19 CAR T cell... 
Read more
Sector
Biotechnology & Medical Research
Calendar
06/28 | 03:00amShareholder meeting
More about the company
Ratings of Autolus Therapeutics plc
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about AUTOLUS THERAPEUTICS PLC
06/21European ADRs Rise Sharply in Tuesday Trading
MT
06/15European ADRs Move Higher in Wednesday Trading
MT
06/14Truist Securities Adjusts Price Target for Autolus Therapeutics to $11 From $13, Mainta..
MT
06/13European ADRs Fall Sharply Lower in Monday Trading
MT
06/13TRANSCRIPT : Autolus Therapeutics plc - Special Call
CI
06/10Autolus Therapeutics Presents Clinical Data Updates at the European Hematology Associat..
GL
06/10Autolus Therapeutics Presents Clinical Data Updates at the European Hematology Associat..
AQ
06/09European ADRs Move Lower in Thursday Trading
MT
06/01AUTOLUS THERAPEUTICS : Notice of Annual General Meeting - Form 6-K
PU
06/01European ADRs Move Lower in Wednesday Trading
MT
05/31Autolus to hold Annual General Meeting (AGM) of Shareholders on Tuesday, June 28, 2022
GL
05/31Autolus to hold Annual General Meeting (AGM) of Shareholders on Tuesday, June 28, 2022
GL
05/31European ADRs Nudge Higher in Tuesday Trading
MT
05/27European ADRs Move Higher in Friday Trading
MT
05/27Autolus Therapeutics to Participate in the Jefferies Healthcare Conference, being held ..
GL
More news
News in other languages on AUTOLUS THERAPEUTICS PLC
06/21Les ADR européens en forte hausse dans les échanges de mardi
06/15Les ADR européens sont en hausse mercredi
06/13Les ADR européens chutent fortement dans les échanges de lundi
06/09Les ADR européens sont en baisse jeudi
06/01Les ADR européens sont en baisse mercredi
More news
Analyst Recommendations on AUTOLUS THERAPEUTICS PLC
More recommendations
Chart AUTOLUS THERAPEUTICS PLC
Duration : Period :
Autolus Therapeutics plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AUTOLUS THERAPEUTICS PLC
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 2,57 $
Average target price 11,39 $
Spread / Average Target 343%
EPS Revisions
Managers and Directors
Christian Martin Itin Chief Executive Officer & Director
Lucinda Crabtree Chief Financial Officer
John H. Johnson Non-Executive Chairman
Martin Pulé Chief Scientific Officer & Senior Vice President
David Brochu Vice President-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
AUTOLUS THERAPEUTICS PLC-50.48%234
GILEAD SCIENCES, INC.-13.12%79 122
VERTEX PHARMACEUTICALS33.22%74 821
REGENERON PHARMACEUTICALS, INC.-3.01%65 993
WUXI APPTEC CO., LTD.-13.42%44 742
BIONTECH SE-48.01%32 574